Bausch Health

BHCApproved

Bausch Health Companies Inc. is a multinational company dedicated to improving people's lives through its portfolio of pharmaceutical, medical device, and over-the-counter products. Its strategy revolves around its core therapeutic areas, leveraging a mix of in-house R&D and strategic acquisitions, most notably the Bausch + Lomb eye health business. The company is executing a turnaround plan focused on debt reduction, portfolio optimization, and growth in key segments like gastroenterology and aesthetics to drive long-term shareholder value.

Market Cap

$1.9B

Employees

17,000-20,000

Focus

Small Molecules

BHC · Stock Price

USD 5.0117.81 (-78.05%)

Historical price data

AI Company Overview

Technology Platform

Bausch Health operates as a diversified specialty pharmaceutical company, leveraging a business model centered on the acquisition, in-licensing, and lifecycle management of late-stage and commercial-stage therapeutic products and medical devices.

Pipeline Snapshot

248

248 drugs in pipeline, 86 in Phase 3

Drug	Indication	Stage
Bexarotene	Refractory Cutaneous T-cell Lymphoma	Approved
Brodalumab + Brodalumab	Psoriasis	Approved
Rifaximin 550 MG Oral Tablet [XIFAXAN]	Pouchitis	Approved
Polyethylene glycol + Oral sodium phosphate solution	Colon Cleansing	Approved
Contrave 8Mg-90Mg Extended-Release Tablet + Placebo	Obesity	Approved

FDA Approved Drugs

CABTREONDAOct 20, 2023

ARAZLONDADec 18, 2019

DUOBRIINDAApr 25, 2019

Opportunities

Growth opportunities include expanding indications for key assets like Xifaxan, increasing market penetration for recent GI launches (Trulance), and leveraging the global footprint of the separated Bausch + Lomb.

Debt reduction could significantly improve financial flexibility and valuation.

Risk Factors

Key risks include the substantial debt burden, impending patent expirations for core products (e.g., Xifaxan), intense competition in all therapeutic areas, execution risks in the turnaround plan, and lingering legal/regulatory liabilities.

Competitive Landscape

Bausch Health competes with large pharmaceutical companies (AbbVie, Takeda, Pfizer) in gastroenterology, major aesthetics players (Allergan Aesthetics, Merz), and eye care giants (Alcon, J&J Vision). Its differentiation relies on specialized commercial focus, established brands, and a portfolio addressing chronic care needs.

Publications

Pipeline

248

FDA Approvals